Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (25)

2024

  1. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Natural History of MYH7-Related Dilated Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 80, Núm. 15, pp. 1447-1461

  2. RICORS2040: The need for collaborative research in chronic kidney disease

    Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387

2020

  1. Transcatheter mitral repair for functional mitral regurgitation according to left ventricular function: A real-life propensity-score matched study

    Journal of Clinical Medicine, Vol. 9, Núm. 6, pp. 1-14

2019

  1. A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics

    Reumatologia Clinica, Vol. 15, Núm. 3, pp. 156-164

  2. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study

    Reumatologia Clinica, Vol. 15, Núm. 2, pp. 102-108

2017

  1. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294

  2. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  2. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

  3. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

2015

  1. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death

    Medicine (United States), Vol. 94, Núm. 43

  2. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Analysis of ancestral and functionally relevant CD variants in systemic lupus erythematosus patients

    PLoS ONE, Vol. 9, Núm. 11

2012

  1. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2011

  1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

    Arthritis Research and Therapy, Vol. 13, Núm. 4

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus

    Clinical and Experimental Rheumatology

  2. No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus

    Lupus, Vol. 18, Núm. 3, pp. 230-234